psoriasis

Johnson & Johnson’s Tremfya outshines IL-17 inhibitors as plaque psoriasis treatment
Johnson & Johnson’s Tremfya outshines IL-17 inhibitors as plaque psoriasis treatment
Clinical Trials Arena
JNJ
Janssen
Tremfya
psoriasis
real world data
Flag link:
Immunic punts psoriasis, prostate cancer programs to narrow focus onto multiple sclerosis, celiac disease
Immunic punts psoriasis, prostate cancer programs to narrow focus onto multiple sclerosis, celiac disease
Fierce Biotech
Immunic
prostate cancer
psoriasis
MS
multiple sclerosis
celiac disease
Flag link:
Acquired patents aid J&J defense of top-selling drug from biosimilar challenge
Acquired patents aid J&J defense of top-selling drug from biosimilar challenge
BioPharma Dive
Amgen
JNJ
Stelara
psoriasis
patents
biosimilars
Flag link:
Biohaven strikes a deal to take TYK2 drugs in a new direction
Biohaven strikes a deal to take TYK2 drugs in a new direction
BioPharma Dive
Biohaven
Pfizer
Hangzhou Highlightll
psoriasis
Flag link:
AbbVie’s Skyrizi hits the spot in refractory psoriasis
AbbVie’s Skyrizi hits the spot in refractory psoriasis
Pharmaphorum
AbbVie
Skyrizi
psoriasis
Flag link:
Takeda focuses on ‘diverse’ pipeline prospects on heels of two acquisitions
Takeda focuses on ‘diverse’ pipeline prospects on heels of two acquisitions
Endpoints
Takeda
Nimbus Therapeutics
Hutchmed
colorectal cancer
psoriasis
fruquintinib
Flag link:
UCB's bimekizumab finally back on the FDA's review list after May rejection
UCB's bimekizumab finally back on the FDA's review list after May rejection
Fierce Pharma
UCB Pharma
psoriasis
bimekizumab
FDA
Flag link:
Dr. Reddy's subsidiary hits the pause button on drug development for psoriasis
Dr. Reddy's subsidiary hits the pause button on drug development for psoriasis
Endpoints
Dr Reddy's
psoriasis
Aurigene
clinical trials
AUR101
Flag link:
Nimbus hopes to best Bristol’s Sotyktu
Nimbus hopes to best Bristol’s Sotyktu
EP Vantage
Bristol Myers Squibb
Sotyktu
Nimbus
NDI-034858
psoriasis
Flag link:
The other shoe drops for Immunic
The other shoe drops for Immunic
EP Vantage
Immunic
IMU-935
psoriasis
Flag link:
A biologic’s efficacy in a pill: Dice posts first human data for oral psoriasis med
A biologic’s efficacy in a pill: Dice posts first human data for oral psoriasis med
MedCity News
DiCE Therapeutics
biologics
psoriasis
DC-806
Flag link:
Nimbus raises $125M to advance rival to Bristol Myers’ new psoriasis drug
Nimbus raises $125M to advance rival to Bristol Myers’ new psoriasis drug
BioPharma Dive
Nimbus Therapeutics
psoriasis
Bristol Myers Squibb
Sotyktu
Flag link:
Bristol Myers gets FDA approval for new type of psoriasis drug
Bristol Myers gets FDA approval for new type of psoriasis drug
BioPharma Dive
Bristol Myers Squibb
Sotyktu
FDA
psoriasis
Flag link:
Ventyx touts early data for potential rival to Bristol Myers psoriasis drug
Ventyx touts early data for potential rival to Bristol Myers psoriasis drug
BioPharma Dive
Ventyx Biosciences
clinical trials
Bristol Myers Squibb
psoriasis
VTX958
deucravacitinib
Flag link:
Pursuing AbbVie and J&J, Innovent hits primary endpoint in phase 2 psoriasis trial
Pursuing AbbVie and J&J, Innovent hits primary endpoint in phase 2 psoriasis trial
Fierce Biotech
Innovent
AbbVie
JNJ
monoclonal antibodies
psoriasis
clinical trials
Flag link:
Plaque psoriasis and psoriatic arthritis: trials to watch in 2022
Plaque psoriasis and psoriatic arthritis: trials to watch in 2022
Clinical Trials Arena
clinical trials
psoriasis
psoriatic arthritis
Lipidor
AKP-02
Amgen
ABP-654
Hengyi
HPP-737
Galapagos
Jyseleca
Flag link:
FDA Action Alert: Incyte, Arcutis Await Decisions in Vitiligo, Psoriasis
FDA Action Alert: Incyte, Arcutis Await Decisions in Vitiligo, Psoriasis
BioSpace
FDA
Incyte
Arcutis Biotherapeutics
Opzelura
vitiligo
roflumilast
psoriasis
Flag link:
Bristol Myers Squibb, with new positive lupus data in hand, readies TYK2 inhibitor for final test
Bristol Myers Squibb, with new positive lupus data in hand, readies TYK2 inhibitor for final test
Fierce Biotech
Bristol Myers Squibb
lupus
psoriasis
deucravacitinib
Flag link:
FDA approves Roivant drug, the first novel topical plaque psoriasis med in 25 years
FDA approves Roivant drug, the first novel topical plaque psoriasis med in 25 years
MedCity News
Roivant
Vtama
FDA
psoriasis
plaque psoriasis
Flag link:
J&J's crown jewel Stelara faces another potential rival as biosim player Alvotech touts trial win
J&J's crown jewel Stelara faces another potential rival as biosim player Alvotech touts trial win
Fierce Pharma
Alvotech
Teva Pharmaceutical
JNJ
Stelara
AVT04
biosimilars
psoriasis
Flag link:

Pages